Absci Corp
ABSI
Company Profile
Business description
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Contact
18105 SE Mill Plain Boulevard
VancouverWA98683
USAT: +1 360 949-1041
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
140
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,853.80 | 8.20 | 0.09% |
| CAC 40 | 8,077.80 | 3.63 | -0.04% |
| DAX 40 | 25,408.64 | 142.11 | 0.56% |
| Dow JONES (US) | 51,828.62 | 478.64 | 0.93% |
| FTSE 100 | 10,695.25 | 15.26 | 0.14% |
| HKSE | 24,510.09 | 251.04 | -1.01% |
| NASDAQ | 27,068.72 | 129.34 | 0.48% |
| Nikkei 225 | 66,954.35 | 590.15 | 0.89% |
| NZX 50 Index | 13,826.87 | 15.76 | 0.11% |
| S&P 500 | 7,743.41 | 39.28 | 0.51% |
| S&P/ASX 200 | 8,676.30 | 11.30 | 0.13% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |